Cinryze
Named-patient access overview. Cinryze is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cinryze (C1 esterase inhibitor, human) is a plasma-derived C1-inhibitor concentrate marketed by Takeda. The US Food and Drug Administration first approved Cinryze in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), with a paediatric prophylaxis indication added in subsequent supplements. Cinryze is administered as a 1,000-unit intravenous infusion every 3 or 4 days for routine prevention, typically self-infused at home after training or given in an HAE specialty centre. Treatment is prescribed and overseen by an allergist-immunologist or HAE-experienced clinician. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cinryze
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cinryze is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Cinryze in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cinryze
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.